Scientific Sessions 2025  /  Shifting Paradigms in Lipid Management for ASCVD Risk  /  From management to cure? Assessing the promise of gene therapy for hyperlipidemia
Logo

American Heart Association

  128
  0

Final ID:

From management to cure? Assessing the promise of gene therapy for hyperlipidemia

  • Musunuru, Kiran  ( University of Pennsylvania , Philadelphia , Pennsylvania , United States )
    • Author Disclosures:
    Kiran Musunuru: DO have relevant financial relationships ; Individual Stocks/Stock Options:Verve Therapeutics:Active (exists now) ; Research Funding (PI or named investigator):Beam Therapeutics:Active (exists now) ; Research Funding (PI or named investigator):Nava Therapeutics:Active (exists now) ; Advisor:Capstan Therapeutics:Active (exists now) ; Advisor:LEXEO Therapeutics:Active (exists now) ; Ownership Interest:Variant Bio:Active (exists now) ; Advisor:Verve Therapeutics:Active (exists now)
Meeting Info:

Scientific Sessions 2025

2025

New Orleans, Louisiana

Session Info:

Shifting Paradigms in Lipid Management for ASCVD Risk

Saturday, 11/08/2025 , 01:30PM - 02:45PM

Main Event

More abstracts on this topic:
The ODYSSEY of Lipid Lowering: Navigating the Growing Array of Therapeutics for LDL-C Reduction

Tokgozoglu Lale

Efficacy and Safety of Enlicitide, an Oral PCSK9 Inhibitor, for Lowering LDL Cholesterol in Adults with or At-Risk for ASCVD: The Phase 3 CORALreef Lipids Trial

Navar Ann Marie, Mendizabal Geraldine, Nuez Llota Julio, Zhu Pengfei, Zhuo Min, Ballantyne Christie, Mikhailova Elina, Catapano Alberico, Banka Puja, Blom Dirk, Cadena Alberto, Kourpanidis Susan, Lepor Norman, Tsukamoto Kazuhisa

More abstracts from these authors:
Vascular Discovery Distinguished Lecture: Therapeutic Gene Editing for Cardiovascular and Metabolic Diseases

Musunuru Kiran

CRISPR Clarity: The Time is Now for Gene Editing in Cardiomyopathy

Musunuru Kiran, Olson Eric

You have to be authorized to contact abstract author. Please, Login
Not Available